Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther., 2006, 23(2): 2-8.
Sachs G, Shin J, Vagin O, Lambrecht N, Yakubov I, Munson K. The Gastric H, K ATPase of a Drug Target: past, present, and future. J Clin Gastroenterol, 2007, 41(2): 226-42.
Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management-the Geneva Workshop report. Gut, 1999, 44(2): 1-16.
DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesopha-geal reflux disease. Am J Gastroenterol, 2005, 100: 190-200.
Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary- care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol, 2005, 100: 1237-42.
Tonini M, DeGiorgio R, DePonti F. Novel therapeutic strategies in acid-related disorders. Expert Opin Ther Patents, 2003, 13: 639-49.
Ливзан М.А., Лялюкова Е.А. Гастроэзофагеальная рефлюксная болезнь, рефрактерная к терапии ингибиторами протонной помпы. Клинические наблюдения. Лечащий врач, 2015, 8: 18.
Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther., 2005, 22(3): 10-9. 1949-56.
Ливзан М.А., Кононов А.В. Клинические и фармакоэкономические аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая, 2004, 4: 55-61.
Bate CM, Booth SN, Crowe JP, HepworthJones B, Taylor MD, Richardson PD. Does 40 mg omepra-zole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther, 1993, 7: 501-7.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther, 2001, 23: 1296-310.
Бордин Д.С. Как выбирать ингибитор протонной помпы больному ГЭРБ? Экспериментальная и клиническая гастроэнтерология, 2010, 2: 53-58.
Miner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol, 2003; 98: 2616-20. Scarpignato C, Pelosini I, Di Mario F.Acid suppression therapy: where do we go from here? Dig Dis., 2006; 24: 11-46.
Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary- care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol, 2005; 100: 1237-42.
Persson K. When do ulcer patients take their acid inhibiting medication? Hassle Information, 1993; 7: 19-23.
Nexium (esomeprazole magnesium). Full Prescribing Information. Wilmington, DE: AstraZeneca LP, 2008.
Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol, 2007; 64: 386-90.
Vaz-da-Silva M, Loureiro AI, Nunes T, et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig, 2005; 25: 391-9.
Bergstrand R, Grind M, Nyberg G, Olafsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standard breakfast. Clin Drug Invest, 1995; 9: 67-71.
Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol, 2011; 5: 439-445.
Kukulka M, et al. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol, 2011; 4: 213-20.
Zhang W, et al. Pharmacokinetic, pharmacodynamic, and safety evaluation of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology, 2007; 132(4 Suppl 2) A487).
Vakily M et al. Pharmacokinetics and pharma-codynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansopra-zole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin, 2009; 25: 627-38.
Lee R, Vakily M, Mulford D, Wu J, Atkinson S. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment Pharmacol Ther, 2009, 29: 824-833.
Lee R, Mulford D, Wu J, Atkinson S. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther, 2010; 31: 1001-1011.
Fass R, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther, 2009; 29: 1261-72.
Nocon M, Labenz J, Jaspersen D, et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care -results from the ProGERD study. Aliment Pharmacol Ther, 2007; 25: 715-22.
Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson S.N. Clinical trial: dexlanso-prazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther., 2009; 29: 742-754.
Howden CW, et al. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther, 2009; 30: 895-90.
Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol, 2004; 2: 656-64.
Fass R, Chey W, Zakko S, Andhivarothai N, Palmer R, Perez M., Atkinson S. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther, 2009; 29: 1261-1272.
Mody R, Bolge SC, Kannan H et al. Eff ects of gastroesophageal refl ux disease on sleep and outcomes. Clin Gastroenterol Hepatol, 2009; 7: 953-9.
Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drag interaction studies with dex-lansoprazoli.modified relase (TAK-390MR), proton pomp imhibitor with a dual delayed-relase formulation; results of four randomized double-blind, crossover, single - centre studies. Clin Drag Investig. 2009; 29: 35-50.